Chimeric TGFB Signaling Receptor (CTSR) Enabled Anti-B7H3 CAR T-cell Therapy in Children and AYA with Recurrent Solid Tumors
Grant Award Details
Grant Type:
Grant Number:
CLIN1-15337
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$5,954,784
Status:
Pre-Active
Grant Application Details
Application Title:
Chimeric TGFB Signaling Receptor (CTSR) Enabled Anti-B7H3 CAR T-cell Therapy in Children and AYA with Recurrent Solid Tumors
Public Abstract:
Therapeutic Candidate or Device
Engineered CAR T-cells are enhanced to allow their survival in solid tumors
Indication
Children, adolescents and young adults with variety of solid tumors but focus on sarcomas and neuroblastomas
Therapeutic Mechanism
Engineered T-cells are expanded and infused back to the patients. The additional mechanisms engineered in these cells allows them to survive in the hostile environment of a solid tumor and kill the tumor cells.
Unmet Medical Need
The survival of children and young adults with metastatic sarcomas has not significantly changed over the last 40 years. The young children and adults also have significant morbidity due to the toxic effects of current standard therapies (e.g. chemotherapy, radiation therapy)
Project Objective
Submission of Phase 1 trial IND
Major Proposed Activities
Engineered CAR T-cells are enhanced to allow their survival in solid tumors
Indication
Children, adolescents and young adults with variety of solid tumors but focus on sarcomas and neuroblastomas
Therapeutic Mechanism
Engineered T-cells are expanded and infused back to the patients. The additional mechanisms engineered in these cells allows them to survive in the hostile environment of a solid tumor and kill the tumor cells.
Unmet Medical Need
The survival of children and young adults with metastatic sarcomas has not significantly changed over the last 40 years. The young children and adults also have significant morbidity due to the toxic effects of current standard therapies (e.g. chemotherapy, radiation therapy)
Project Objective
Submission of Phase 1 trial IND
Major Proposed Activities
- Generate the virsues needed to engineer the T-cells
- Establish the processes to make the engineered T-cells for patients
- Establish the protocols and regulatory documents to conduct the trial and apply for FDA approval
Statement of Benefit to California:
The engineered T-cells we are proposing could significantly help children and young adults living in California with devastating diagnosis of cancers affecting their bones and muscles. If successful , this therapy could also benefit other adult solid tumors.